- Home
- NPCT vs MRVI Comparison
NPCT vs MRVI Comparison
Compare NPCT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- MRVI
- Stock Information
- Founded
- NPCT 2020
- MRVI 2014
- Country
- NPCT United States
- MRVI United States
- Employees
- NPCT N/A
- MRVI N/A
- Industry
- NPCT Investment Managers
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- MRVI Health Care
- Exchange
- NPCT Nasdaq
- MRVI Nasdaq
- Market Cap
- NPCT 314.6M
- MRVI 371.8M
- IPO Year
- NPCT N/A
- MRVI 2020
- Fundamental
- Price
- NPCT $10.91
- MRVI $2.42
- Analyst Decision
- NPCT
- MRVI Hold
- Analyst Count
- NPCT 0
- MRVI 10
- Target Price
- NPCT N/A
- MRVI $5.84
- AVG Volume (30 Days)
- NPCT 107.1K
- MRVI 1.5M
- Earning Date
- NPCT 01-01-0001
- MRVI 08-11-2025
- Dividend Yield
- NPCT 9.82%
- MRVI N/A
- EPS Growth
- NPCT N/A
- MRVI N/A
- EPS
- NPCT N/A
- MRVI N/A
- Revenue
- NPCT N/A
- MRVI $219,830,000.00
- Revenue This Year
- NPCT N/A
- MRVI N/A
- Revenue Next Year
- NPCT N/A
- MRVI $7.23
- P/E Ratio
- NPCT N/A
- MRVI N/A
- Revenue Growth
- NPCT N/A
- MRVI N/A
- 52 Week Low
- NPCT $8.58
- MRVI $1.67
- 52 Week High
- NPCT $10.63
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- NPCT 48.99
- MRVI 49.60
- Support Level
- NPCT $10.82
- MRVI $2.28
- Resistance Level
- NPCT $10.98
- MRVI $2.47
- Average True Range (ATR)
- NPCT 0.12
- MRVI 0.14
- MACD
- NPCT -0.01
- MRVI -0.01
- Stochastic Oscillator
- NPCT 48.15
- MRVI 27.45
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.